7/103 sources · 3 publishersUpdated Nov 9, 17:34 UTC
Piper Sandler lifts Moderna price target to $305, citing strong Q3 sales and higher revenue outlook
Piper Sandder raised its price target on Moderna to $305 from $230 after the company posted a third‑quarter 2026 revenue of $1.3 billion, up 29% year over year, and earnings of $0.38 per share. The firm also noted Moderna’s increased 2026 revenue guidance of 15%‑25% growth and its melanoma vaccine partnership with Merck. The upgrade helped the stock jump about 9% on the day.
Why it matters
The higher target may support further buying pressure as investors adjust expectations for Moderna’s revenue growth and upcoming cancer vaccine approval. Piper Sandler’s view is reflected in the stock’s immediate 9% rise.
Key facts
- 1Piper Sandler raised its price target on Moderna to $305 from $230. investing.com
- 2Moderna reported third‑quarter 2026 revenue of $1.3 billion, a 29% year‑over‑year increase. investing.com
- 3Moderna earned $0.38 per share in Q3 2026, improving from a loss of $0.51 per share a year earlier. investing.com
- 4The company increased its 2026 revenue guidance to 15%‑25% growth. finance.yahoo.com
- 5Moderna ended the quarter with cash of $8 billion and long‑term debt of $3.19 billion. investing.com
- 6Piper Sandler expects a blockbuster melanoma vaccine approval in 2027 from Moderna’s partnership with Merck. investing.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.